Publications des scientifiques de l'IRD

Collins I., Cairns J., Le Coeur Sophie, Pagdi K., Ngampiyaskul C., Layangool P., Borkird T., Na-Rajsima S., Wanchaitanawong V., Jourdain Gonzague, Lallemant Marc. (2013). Five-year trends in antiretroviral usage and drug costs in HIV-infected children in Thailand. Jaids-Journal of Acquired Immune Deficiency Syndromes, 64 (1), p. 95-102. ISSN 1525-4135.

Titre du document
Five-year trends in antiretroviral usage and drug costs in HIV-infected children in Thailand
Année de publication
2013
Type de document
Article référencé dans le Web of Science WOS:000330451600017
Auteurs
Collins I., Cairns J., Le Coeur Sophie, Pagdi K., Ngampiyaskul C., Layangool P., Borkird T., Na-Rajsima S., Wanchaitanawong V., Jourdain Gonzague, Lallemant Marc
Source
Jaids-Journal of Acquired Immune Deficiency Syndromes, 2013, 64 (1), p. 95-102 ISSN 1525-4135
Background: As antiretroviral treatment (ART) programs mature, data on drug utilization and costs are needed to assess durability of treatments and inform program planning. Methods: Children initiating ART were followed up in an observational cohort in Thailand. Treatment histories from 1999 to 2009 were reviewed. Treatment changes were categorized as: drug substitution (within class), switch across drug class (non nucleoside reverse-transcriptase inhibitors (NNRTI) to/from protease inhibitor (PI)), and to salvage therapy (dual PI or PI and NNRTI). Antiretroviral drug costs were calculated in 6-month cycles (US 2009 prices). Predictors of high drug cost including characteristics at start of ART (baseline), initial regimen, treatment change, and duration on ART were assessed using mixed-effects regression models. Results: Five hundred seven children initiated ART with a median 54 (interquartile range, 36-72) months of follow-up. Fifty-two percent had a drug substitution, 21% switched across class, and 2% to salvage therapy. When allowing for drug substitution, 78% remained on their initial regimen. Mean drug cost increased from 251 to 428 per child per year in the first and fifth year of therapy, respectively. PI-based and salvage regimens accounted for 16% and 2% of treatments prescribed and 33% and 5% of total costs, respectively. Predictors of high cost include baseline age >= 8 years, non nevirapine-based initial regimen, switch across drug class, and to salvage regimen (P < 0.005). Conclusions: At 5 years, 21% of children switched across drug class and 2% received salvage therapy. The mean drug cost increased by 70%. Access to affordable second-and third-line drugs is essential for the sustainability of treatment programs.
Plan de classement
Entomologie médicale / Parasitologie / Virologie [052] ; Santé : aspects socioculturels, économiques et politiques [056]
Description Géographique
THAILANDE
Localisation
Fonds IRD [F B010061740]
Identifiant IRD
fdi:010061740
Contact